Posted by
Biosimilars in 2020: All eyes on how Indian pharmas cash in on investments after betting on foreign markets

Biosimilars in 2020: All eyes on how Indian pharmas cash in on investments after betting on foreign markets

While over 50 different biosimilars already exist in the Indian market, the big money lies launching these drugs in Europe and the United States It has been more than a decade since Indian pharmaceutical companies began looking at the biosimilar opportunity. It is not an easy space to be in and quite unlike their traditional […]

Posted by
FDA approves new generic valsartan to make up for drug shortage

FDA approves new generic valsartan to make up for drug shortage

FDA approves new generic valsartan to make up for drug shortage (CNN)- The US Food and Drug Administration approved a new generic of valsartan on Tuesday to help relieve the recent shortage of the medicine, which is used to treat high blood pressure. Since last summer, the FDA has issued multiple recalls of generic valsartan […]

Posted by
Generics vs. Biosimilars: Similar but Different Advantages

Generics vs. Biosimilars: Similar but Different Advantages

Biosimilars have the same clinical effect as a generic but are only as similar to the original branded drug as validation technologies can confirm. When a drug company introduces a costly new drug, they can do so because they have an exclusive patent on it. Once drug patents expire, pharmaceutical companies can copy that branded […]

Posted by
Expanding from generics to biosimilars in India

Expanding from generics to biosimilars in India

The first biosimilar in India was approved in 2000, and, with the help of legislation and regulation from the Indian Government, the market has continued to grow since, reaching a value of $2.2bn in 2017. However, biosimilars remain challenging to manufacture for Indian pharmaceutical companies, at the emerging end of the market. India has firmly […]